EPO and inflammatory bowel disease: Both EPO and cEPO have been shown to decrease the production of inflammatory mediators like TNF-α, IL-1β, and lymphocytes, which are associated with conditions such as IBD, and increase the levels of IL-10, indicating that cEPO can effectively counteract inflammation [15].